A historical clinical trial with an adenoviral vector encoding the OTC gene caused the death of one late-onset OTCD patient receiving a high-dose (HD) vector due to a severe immune response syndrome triggered by innate immunity against the vector capsid.5 Here, OTC is linked to ornithine carbamoyltransferase deficiency.